NetScientific PLC PDS Announces Trial of its Lead Product, PDS0101 (1063P)
05 Junho 2020 - 5:15AM
UK Regulatory
TIDMNSCI
RNS Number : 1063P
NetScientific PLC
05 June 2020
NetScientific plc
("NetScientific" or the "Company")
PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy
Product, PDS0101, in Combination with Chemoradiotherapy in Advanced
Cervical Cancer
NetScientific plc (AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that its portfolio company PDS
Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced
yesterday a Phase 2 clinical trial to evaluate its lead
immunotherapy product, PDS0101, in combination with standard of
care chemoradiotherapy for treatment of locally advanced cervical
cancer.
NetScientific holds 7.18% of PDS' undiluted share capital.
The full details of the announcement are set out below and can
be found here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/393-iotechnnounceslinicalrialoftseadmmunother20200604
# # #
PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy
Product, PDS0101, in Combination with Chemoradiotherapy in Advanced
Cervical Cancer
FLORHAM PARK, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company's proprietary
Versamune(R) T-cell activating technology, today announced a Phase
2 clinical trial to evaluate its lead immunotherapy product,
PDS0101, in combination with standard of care chemoradiotherapy for
treatment of locally advanced cervical cancer.
The clinical trial will be conducted at The University of Texas
MD Anderson Cancer Center and the Lyndon B. Johnson Hospital in
Houston by Ann H. Klopp, M.D., Ph.D., Associate Professor of
Radiation Oncology and Olsi Gjyshi, M.D., Ph.D. The clinical trial
will investigate the safety and anti-tumor efficacy of the
PDS0101-chemoradiation combination, and their correlation with
critical biomarkers of an immune response in patients with locally
advanced cervical cancer.
On September 19, 2019, PDS Biotech announced the results of a
PDS0101 Phase 1 clinical study in cervical neoplasia (pre-cervical
cancer) patients. PDS0101 is being developed to treat multiple
cancers associated with HPV infection, including anal, cervical and
head and neck cancers. In the Phase 1 study, PDS0101 demonstrated
potent in vivo induction of active killer T-cells that target
cancer cells containing the cancer-causing HPV proteins, as well as
an excellent safety profile with no limiting toxicities. Treatment
with PDS0101 resulted in complete lesion regression in most of the
patients. HPV infection is responsible for over 99% of cervical
cancers. PDS Biotech currently anticipates initiating this clinical
study within a few months.
"We are pleased to announce this Phase 2 clinical trial being
performed to further validate our novel Versamune(R)-based
immunotherapy platform and lead asset PDS0101," said Dr. Frank
Bedu-Addo, CEO of PDS Biotech. "We look forward to investigating
PDS0101 as a potentially safe and effective immunotherapeutic
combination with standard of care chemoradiotherapy to improve the
treatment options for women with locally advanced cervical
cancer."
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of cancer immunotherapies and infectious disease
vaccines based on the Company's proprietary Versamune(R) T-cell
activating technology platform. Versamune(R) effectively delivers
disease-specific antigens for in vivo uptake and processing, while
also activating the critical type 1 interferon immunological
pathway, resulting in production of potent disease-specific killer
T-cells as well as neutralizing antibodies. PDS Biotech has
engineered multiple therapies, based on combinations of
Versamune(R) and disease-specific antigens, designed to train the
immune system to better recognize disease cells and effectively
attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech's lead candidate, PDS0101, combines the utility of
the Versamune(R) platform with targeted antigens in HPV-expressing
cancers. In separate partnerships with Merck and Co. and the
National Cancer Institute (NCI), PDS Biotech is preparing to
initiate two additional Phase 2 studies in head and neck cancer and
in HPV-related advanced cancer respectively.
# # #
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Following the
publication of this announcement, this inside information is now
considered to be in the public domain.
For more information, please contact:
NetScientific
Ilian Iliev, CEO Tel: +44 (0)20 3514 1800
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666
MO PR ADVISORY (Press Contact)
Mo Noonan Tel: +44 (0)78 7644 4977
About NetScientific
NetScientific PLC is a transatlantic healthcare IP
commercialisation Group focused on technologies and companies that
have the potential to treat chronic disease and significantly
improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCVELBBBQLFBBF
(END) Dow Jones Newswires
June 05, 2020 04:15 ET (08:15 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024